Pace MI
Protocol Number: NA
Therapeutic Area: Cardiology
Summary:
Patients within one month of a myocardial infarction who have either bradycardia or heart block contraindications to beta blockers will be randomized to received either standard post myocardial infarction therapy or standard therapy plus a pacemaker and beta-blockers.
Inclusion Criteria:
- >30 years with recent (< 30 days) history of MI by
- CPK elevation > 2x or troponin > 3x UL
- EKG changes and/or symptoms consistent with MI
- Either of the following:
- Bradycardia or heart block contraindication to beta-blocker therapy defined by:
- Resting (awake) heart rate < 55 bpm on 2 consecutive days in the absence of treatment with rate-slowing medications ( i.e. diltiazem, verapamil)
- Sinus pauses (>2 seconds) during day
- PR interval > 260 msec in the absence of medications that prolong AV nodal conduction time (digoxin, diltiazem, verapamil)
- Second-degree AV block, type I at rest (and awake)
- Documented symptomatic bradycardia due to beta-blocker therapy
- Bradycardia or heart block contraindication to beta-blocker therapy defined by:
Exclusion Criteria:
- Unstable or class IV angina
- Absolute medical contraindications to beta-blockers (i.e. severe bronchospastic disease, systolic blood pressure <90 mmHg)
*Additional Eligibility Criteria Exist*
Center Name: Mercy Research Institute at Mercy Hospital
Contact Information: Mercy Research Institute Clinical Trial Coordinators
Address: 3659 South Miami Avenue, Suite 3001, Miami, Florida 33133
Phone: (305) 854-4400, ext. 2312
Fax: (305) 285-2791
E-mail: asilva@mercymiami.org